Up to date with medac

Join us at the World ADC 2026 in London: Europe's leading ADC conference, bringing together global experts to drive innovation in the development, efficacy, safety and manufacturing of ADCs and accelerate their use in oncology. Through our partnership with Cerbios under the PROVEO brand, we offer a fully integrated ADC solution—from bulk drug substance to finished drug product—with scalable capacity from clinical phases to commercial supply. We would be delighted to support your next ADC project with our deep experience in aseptic fill & finish and high-potency injectables. Ready to start? Book your meeting below!

The recent completion of patient enrollment in UroGen Pharma’s Phase 3 UTOPIA trial marks a major step forward in the development of UGN-103 (mitomycin) for intravesical solution under investigation for the treatment of recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). medac CDMO is proud to contribute significantly to this achievement as the development and manufacturing partner for UGN-103....